J&J's Remicade Adds Psoriatic Arthritis Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves the supplemental indication for infliximab; J&J plans to differentiate Remicade from Amgen/Wyeth's Enbrel by highlighting Psoriasis Area Severity Index score improvements and reduction of symptoms of dactylitis and enthesopathy.
You may also be interested in...
Abbott's Humira Approved For Psoriatic Arthritis, First-Line Rheumatoid Arthritis
Abbott will support dedicated sales representatives to detail Humira to dermatologists following psoriatic arthritis approval.
Abbott's Humira Approved For Psoriatic Arthritis, First-Line Rheumatoid Arthritis
Abbott will support dedicated sales representatives to detail Humira to dermatologists following psoriatic arthritis approval.
Centocor’s Remicade Approved For Ulcerative Colitis
Remicade becomes the first biologic approved for ulcerative colitis following a priority review, J&J subsidiary Centocor says.